Key Stats for Edwards Lifesciences Stock
- Past-Week Performance: +8.3%
- 52-Week Range: $65.9 to $87.9
- Current Price: $87.2
What Happened?
Edwards Lifesciences (EW) trades just $0.71 below its 52-week high of $87.89 while simultaneously resolving an EU antitrust investigation, launching SAPIEN M3, and presenting at three consecutive investor conferences, signaling a company executing without distraction.
Just yesterday, CFO Scott Ullem confirmed at the TD Cowen 46th Annual Health Care Conference that Edwards holds increased confidence in its 8% to 10% full year sales growth and $2.90 to $3.05 adjusted EPS guidance for 2026.
TMTT grew over 40% in Q4 to $156 million and exceeded $545 million for the full year, directly supporting the operating margin expansion trajectory that management targets at 150 basis points for 2026.
CEO Bernard Zovighian stated on the Q4 earnings call that “we are entering 2026 with strength and momentum globally with many growth catalysts in each area across the company,” a claim now backed by confirmed PROGRESS moderate AS data arriving at TCT in December.
With next-gen PASCAL and PASCAL tricuspid U.S. approval both targeting Q4, CLASP II TR data at TCT, and RESILIA 10-year surgical data at ATS in May, Edwards enters a 12-month stretch that could permanently expand its addressable structural heart market.
Wall Street’s Take on EW Stock
Edwards’ confirmed EU antitrust resolution on February 16, SAPIEN M3 commercial launch, and three consecutive investor conference appearances through March 11 collectively confirm a company removing overhangs while accelerating its multi-product growth cycle.
Fundamentally, revenue accelerates from $6.1 billion at 11.5% growth in FY 2025 to an estimated $6.7 billion at 9.9% in 2026, while EPS expands 15.5% to $2.96 after compressing 3.2% in FY 2024.
Wall Street shows 16 buys, 5 outperforms, 12 holds, and zero sells against a mean price target of $96.46, implying 10.6% upside from $87.18, with analysts upgrading steadily as TMTT scale and NCD momentum build conviction.
The target range spans $84 on the low end to $110 on the high, where the downside reflects PROGRESS moderate AS data disappointing at TCT in December and the upside hinges on a favorable TAVR NCD final determination in Q4.
What Does the Valuation Model Say?
The mid-case model targets $148.55, implying 70.4% total return over 4.8 years at an 11.7% annualized IRR from today’s $87.18.
That gap exists because the market is pricing Edwards as a single-product TAVR story while TMTT alone grew over 40% in Q4 and targets $740 to $780 million in 2026.
The mispricing becomes clearest when EPS accelerates 15.5% in 2026 yet EW trades just $0.71 below its 52-week high of $87.89 with no P/E expansion priced in.
Sixteen analysts carry buy ratings on EW, the highest buy count in at least five quarters, signaling that institutional conviction is building specifically around the NCD and TMTT scale inflection.
However, if the PROGRESS moderate AS trial data at TCT in December disappoints and the CMS NCD final determination expands less than expected, the $2 billion TMTT 2030 revenue target faces a direct timeline risk.
The June/July CMS TAVR NCD first draft will deliver the first concrete signal on whether asymptomatic coverage expansion and reduced operator requirements are actually in play for 2027.
EW is undervalued at $87.18 given a $148.55 model target and an accelerating multi-product cycle, but the re-rating fully confirms when the NCD draft lands in June and validates the structural heart expansion thesis.
Should You Invest in Edwards Lifesciences?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up EW stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Edwards Lifesciences alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze EW stock on TIKR for Free →
